Dupixent vs Taltz
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Dupixent | US Taltz | |
|---|---|---|
| Generic name | dupilumab | ixekizumab |
| Drug class | IL-4/IL-13 Inhibitor (Biologic) | IL-17A Inhibitor (Biologic) |
| Treats | Eczema, asthma, nasal polyps | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Sanofi/Regeneron | Eli Lilly |
| Year approved | 2017 | 2016 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $390M | $190M |
| Common side effects | Injection site reactions, Eye inflammation (conjunctivitis), Cold sores, Eosinophilia | Injection site reactions, Respiratory infections, Inflammatory bowel disease, Low white blood cell count |
Frequently asked questions
Is Dupixent or Taltz better?
Neither is universally "better." Dupixent (dupilumab) and Taltz (ixekizumab) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Dupixent and Taltz?
Dupixent is a IL-4/IL-13 Inhibitor (Biologic) made by Sanofi/Regeneron, while Taltz is a IL-17A Inhibitor (Biologic) made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Dupixent has the larger estimated TV advertising budget of the two.